Colinz Laboratories Ltd
BSE:531210
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.64
84.48
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
C
|
Colinz Laboratories Ltd
BSE:531210
|
116.5m INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
541.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
278.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
223.2B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.1B EUR |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Colinz Laboratories Ltd
Glance View
Colinz Laboratories Ltd. engages in the manufacture of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectable, ointments, and creams. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-01-13. The firm operates and supplies medicines in the domestic market. The Company’s products include oncology, ayurvedic and nutraceuticals. Its oncology products include imatinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim and pegylated liposome doxorubicin. Its ayurvedic products include anti-diarrheas, anti-pyrectics, anti-inflammatories, anti-spasmodic, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonic, ulcer healing agents, digestive agents, drugs to treat oligospermia and erectile dysfunction, ear drops, uterine tonic, anti-diabetics, and general tonics.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Colinz Laboratories Ltd is 4%, which is below its 3-year median of 6%.
Over the last 3 years, Colinz Laboratories Ltd’s Operating Margin has decreased from 6.1% to 4%. During this period, it reached a low of 4% on Oct 30, 2025 and a high of 7% on Mar 31, 2023.